Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02988986 · ClinicalTrials.gov registry record · Phase 2
TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
A Phase 2 study, sponsored by The Methodist Hospital Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT02988986 is a Phase 2 study that has completed, run by The Methodist Hospital Research Institute. The registered enrollment target is 28 participants.
The verdict
NCT02988986, a Phase 2 study, has completed, sponsored by The Methodist Hospital Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is an open label phase II clinical trial to determine the efficacy, toxicity, and safety of TAK-228 plus tamoxifen in patients with newly diagnosed ER-positive, HER2-negative breast cancer.
Interventions
- DRUG Tamoxifen
- DRUG TAK-228
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2019-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02988986
The ClinicalTrials.gov registry entry for NCT02988986 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tamoxifen is the first listed.
NCT02988986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02988986 about?
NCT02988986 is a clinical study titled "TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer". This is an open label phase II clinical trial to determine the efficacy, toxicity, and safety of TAK-228 plus tamoxifen in patients with newly diagnosed ER-positive, HER2-negative breast cancer.
What is the current status of trial NCT02988986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2017-04-24. Estimated completion is 2019-03-30.
What interventions are being tested in trial NCT02988986?
The interventions under investigation include: Tamoxifen (DRUG), TAK-228 (DRUG).
Who is sponsoring clinical trial NCT02988986?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.